Verastem, Inc.·4

Oct 2, 6:51 PM ET

Le NgocDiep T. MD, PhD 4

4 · Verastem, Inc. · Filed Oct 2, 2018

Insider Transaction Report

Form 4
Period: 2018-09-24
Le NgocDiep T. MD, PhD
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2018-09-24+5,0005,000 total
    Exercise: $2.97From: 2018-09-24Exp: 2028-01-05Common Stock (5,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2018-09-24+70,00070,000 total
    Exercise: $4.63From: 2018-09-24Exp: 2027-10-09Common Stock (70,000 underlying)
Footnotes (2)
  • [F1]On January 5, 2018, the Reporting Person was granted an option to purchase 12,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance milestones by June 30, 2018, by March 31, 2019, and within the first twenty-four (24) months after the achievement of certain net sales targets. 20% of the performance criteria was met on April 6, 2018, resulting in vesting of the option as to 2,500 shares. 40% of the performance criteria was met on September 24, 2018, resulting in vesting of the option as to 5,000 shares.
  • [F2]On October 9, 2017, the Reporting Person was granted an option to purchase 70,000 shares of common stock, to vest in full upon the Issuer's satisfaction of certain performance milestones. Such performance criteria were met on September 24, 2018, resulting in the vesting of the option.

Documents

1 file
  • 4
    edgar.xmlPrimary

    PRIMARY DOCUMENT